Construct: ORF ccsbBroadEn_11605
Construct Description:
- Construct Type:
- ORF
- Other Identifiers:
- ORF000168.1_s300c1, BRDN0000391589
- DNA Barcode:
- None
- Epitope Tag:
- None
- Notes:
- No stop codon in insert
Originally Annotated References:
- Gene:
- RABL2A (11159)
Vector Information:
- Vector Backbone:
- pDONR223
- Pol II Cassette 1:
- n/a
- Pol II Cassette 2:
- n/a
- Selection Marker:
- n/a
- Visible Reporter:
- n/a
- Epitope Tag:
- n/a
Current transcripts matched by this ORF:
Taxon | Gene | Symbol | Description | Transcript | Nuc. Match %[?]A simple nucleotide-based global alignment percentage, calculated as follows: total nt. matches ---------------------------------- aligned length (incl. gaps) |
Prot. Match %[?]A simple amino acid-based global alignment percentage, calculated as follows: total aa. matches ---------------------------------- aligned length (incl. gaps) |
Match Diffs[?]This field may contain sequence annotations in HGVS format. For more information about HGVS annotations, please refer to the HGVS Quick Reference Guide. | |
---|---|---|---|---|---|---|---|---|
1 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354417.2 | 100% | 100% | |
2 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001306158.2 | 97.5% | 97.3% | 671_687delinsAA |
3 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001306159.2 | 97.5% | 97.3% | 671_687delinsAA |
4 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354412.2 | 97.5% | 97.3% | 671_687delinsAA |
5 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354413.2 | 97.5% | 97.3% | 671_687delinsAA |
6 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354414.2 | 97.5% | 97.3% | 671_687delinsAA |
7 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003213.1 | 97.5% | 97.3% | 671_687delinsAA |
8 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003214.1 | 97.5% | 97.3% | 671_687delinsAA |
9 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003215.1 | 97.5% | 97.3% | 671_687delinsAA |
10 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003216.1 | 97.5% | 97.3% | 671_687delinsAA |
11 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_024452575.1 | 97.5% | 97.3% | 671_687delinsAA |
12 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354416.2 | 97% | 96.9% | 408_409insGCA;668_684delinsAA |
13 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_007082.5 | 97% | 96.9% | 408_409insGCA;668_684delinsAA |
14 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_013412.4 | 97% | 96.9% | 408_409insGCA;668_684delinsAA |
15 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003220.1 | 97% | 96.9% | 408_409insGCA;668_684delinsAA |
16 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003222.1 | 97% | 96.9% | 408_409insGCA;668_684delinsAA |
17 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001003789.3 | 96.9% | 96.5% | (many diffs) |
18 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001130919.3 | 96.9% | 96.5% | (many diffs) |
19 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001130920.3 | 96.9% | 96.5% | (many diffs) |
20 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001130921.3 | 96.9% | 96.5% | (many diffs) |
21 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350003.2 | 96.9% | 96.5% | (many diffs) |
22 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350004.2 | 96.9% | 96.5% | (many diffs) |
23 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | XM_017028552.1 | 96.9% | 96.5% | (many diffs) |
24 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | XM_017028555.1 | 96.9% | 96.5% | (many diffs) |
25 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | XM_024452147.1 | 96.9% | 96.5% | (many diffs) |
26 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001130922.3 | 96.5% | 96% | (many diffs) |
27 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350005.2 | 96.5% | 96% | (many diffs) |
28 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350006.2 | 96.5% | 96% | (many diffs) |
29 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350007.2 | 96.5% | 96% | (many diffs) |
30 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_007081.4 | 96.5% | 96% | (many diffs) |
31 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | XM_017028556.1 | 96.5% | 96% | (many diffs) |
32 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003210.1 | 95% | 94.8% | 506_523del;689_705delinsAA |
33 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003211.1 | 95% | 94.8% | 506_523del;689_705delinsAA |
34 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003212.1 | 94.6% | 94.4% | 408_409insGCA;503_520del;686_702delinsAA |
35 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350016.2 | 94.4% | 94% | (many diffs) |
36 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350017.2 | 94.4% | 94% | (many diffs) |
37 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | XM_017028551.1 | 94% | 93.6% | (many diffs) |
38 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354405.2 | 93.4% | 93.3% | 505_534del;701_717delinsAA |
39 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354406.2 | 93.4% | 93.3% | 505_534del;701_717delinsAA |
40 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354407.2 | 93.4% | 93.3% | 505_534del;701_717delinsAA |
41 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354408.2 | 93.4% | 93.3% | 505_534del;701_717delinsAA |
42 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354409.2 | 93.4% | 93.3% | 505_534del;701_717delinsAA |
43 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_006712208.3 | 93.4% | 93.3% | 505_534del;701_717delinsAA |
44 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_006712209.3 | 93.4% | 93.3% | 505_534del;701_717delinsAA |
45 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_011510509.2 | 93.4% | 93.3% | 505_534del;701_717delinsAA |
46 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003203.1 | 93.4% | 93.3% | 505_534del;701_717delinsAA |
47 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003204.1 | 93.4% | 93.3% | 505_534del;701_717delinsAA |
48 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003205.1 | 93.4% | 93.3% | 505_534del;701_717delinsAA |
49 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003207.1 | 93.4% | 93.3% | 505_534del;701_717delinsAA |
50 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001306160.3 | 93% | 92.8% | 408_409insGCA;502_531del;698_714delinsAA |
51 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354410.2 | 93% | 92.8% | 408_409insGCA;502_531del;698_714delinsAA |
52 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_024452573.1 | 93% | 92.8% | 408_409insGCA;502_531del;698_714delinsAA |
53 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350008.2 | 92.8% | 92.4% | (many diffs) |
54 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350009.2 | 92.8% | 92.4% | (many diffs) |
55 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350010.2 | 92.8% | 92.4% | (many diffs) |
56 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350011.2 | 92.8% | 92.4% | (many diffs) |
57 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350012.2 | 92.8% | 92.4% | (many diffs) |
58 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | XM_017028543.1 | 92.8% | 92.4% | (many diffs) |
59 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | XM_017028544.1 | 92.8% | 92.4% | (many diffs) |
60 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | XM_017028546.1 | 92.8% | 92.4% | (many diffs) |
61 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001130923.3 | 92.4% | 92% | (many diffs) |
62 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350013.2 | 92.4% | 92% | (many diffs) |
63 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350014.2 | 92.4% | 92% | (many diffs) |
64 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350015.2 | 92.4% | 92% | (many diffs) |
65 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | XM_017028547.1 | 92.4% | 92% | (many diffs) |
66 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001306161.2 | 69.5% | 69.4% | 216_217ins192;479_495delinsAA |
67 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354421.2 | 69.5% | 69.4% | 216_217ins192;479_495delinsAA |
68 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354423.2 | 69.5% | 69.4% | 216_217ins192;479_495delinsAA |
69 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003226.1 | 69.5% | 69.4% | 216_217ins192;479_495delinsAA |
70 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354424.2 | 69.1% | 68.9% | 216_217ins195;476_492delinsAA |
71 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354418.2 | 66.6% | 66.5% | 216_217ins192;313_342del;509_525delinsAA |
72 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354419.2 | 66.6% | 66.5% | 216_217ins192;313_342del;509_525delinsAA |
73 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003223.1 | 66.6% | 66.5% | 216_217ins192;313_342del;509_525delinsAA |
74 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354426.2 | 60.4% | 60.2% | 0_1ins255;416_432delinsAA |
75 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354425.2 | 57.8% | 57.7% | 0_1ins255;250_279del;446_462delinsAA |
76 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003230.1 | 57.8% | 57.7% | 0_1ins255;250_279del;446_462delinsAA |
77 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354427.2 | 57.3% | 54.5% | 0_1ins196;20_21ins80;395_411delinsAA |
78 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354428.2 | 56.9% | 54.1% | (many diffs) |
79 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_024452576.1 | 54.9% | 52.3% | (many diffs) |
80 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | XM_017028559.2 | 48.4% | 42.1% | (many diffs) |
81 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XR_002959036.1 | 26.8% | 1_200del;609_955del;1218_2500delinsAA | |
82 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NR_148882.2 | 26% | 1_188del;482_483ins112;747_2029delinsAA | |
83 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NR_148881.2 | 26% | 1_192del;486_487ins112;751_2033delinsAA | |
84 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NR_148879.2 | 25.9% | 1_188del;484_485ins115;744_2026delinsAA | |
85 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NR_148880.2 | 22% | (many diffs) | |
86 | mouse | 68708 | Rabl2 | RAB, member RAS oncogene fa... | NM_026817.3 | 84.5% | 82.5% | (many diffs) |
87 | mouse | 68708 | Rabl2 | RAB, member RAS oncogene fa... | XM_006521326.3 | 84.1% | 82.1% | (many diffs) |
88 | mouse | 68708 | Rabl2 | RAB, member RAS oncogene fa... | XM_006521327.3 | 71.6% | 70.9% | (many diffs) |
89 | mouse | 68708 | Rabl2 | RAB, member RAS oncogene fa... | XM_006521329.3 | 52.5% | 49.5% | (many diffs) |
90 | mouse | 68708 | Rabl2 | RAB, member RAS oncogene fa... | XM_011245717.2 | 52.5% | 49.5% | (many diffs) |
Sequence Information
Note: uppercase bases indicate empirically verified sequence.
- ORF start:
- 69
- ORF end:
- 741
- ORF length:
- 672
- Sequence:
-
1 gttcgttgca acaaattgat gagcaatgct tttttataat gccaacttTG TACAAAAAAG 61 TTGGCACCAT GGCAGAAGAC AAAACCAAAC CGAGTGAGTT GGACCAAGGG AAGTATGATG 121 CTGATGACAA CGTGAAGATC ATCTGCCTGG GAGACAGCGC AGTGGGCAAA TCCAAACTCA 181 TGGAGAGATT TCTCATGGAT GGCTTTCAGC CACAGCAGCT GTCCACGTAC GCCCTGACCC 241 TGTACAAGCA CACAGCCACG GTAGATGGCA AGACCATCCT TGTGGACTTT TGGGACACGG 301 CAGGCCAGGA GCGGTTCCAG AGCATGCATG CCTCCTACTA CCACAAGGCC CATGCCTGCA 361 TCATGGTGTT TGATATACAG AGGAAAGTCA CCTATAGGAA CCTGAGCACC TGGTATACAG 421 AGCTTCGGGA GTTCAGGCCA GAGATCCCAT GCATCGTGGT GGCCAATAAA ATTGATGCAG 481 ACATAAACGT GACCCAAAAA AGCTTCAATT TTGCCAAGAA GTTCTCCCTG CCCCTGTATT 541 TCGTCTCGGC TGCTGATGGT ACCAATGTTG TGAAGCTCTT CAATGATGCA ATTCGATTAG 601 CTGTGTCTTA CAAACAGAAC TCCCAGGACT TCATGGATGA GATTTTTCAG GAGCTCGAGA 661 ACTTCAGCTT GGAGCAGGAA GAGGAGGACG TGCCAGACCA GGAACAGAGC AGCAGCATCG 721 AGACCCCATC AGAGGAGGAA TTGCCAACTT TCTTGTACAA AGTtggcatt ataagaaagc 781 attgcttatc aatttgttgc aacgaac